Protective autoimmunity in cancer (review)

Area of Science:

• Immunology
• Oncology
• Autoimmunity

Background:

• Immune surveillance combats transformed cells, with naturally occurring antibodies acting as a first defense against cancer.
• Early detection of abnormal cells is critical for patient survival, as not all malignant cells progress to invasive disease.

Purpose of the Study:

• To investigate the role of naturally occurring antibodies in cancer detection and patient survival.
• To explore the potential of autoantibodies and immune checkpoint inhibitors in cancer treatment and prevention.

Main Methods:

• Utilized human hybridoma technology to isolate tumor-binding IgM antibodies.
• Analyzed naturally occurring autoantibody responses in cancer patients and healthy donors.
• Examined the expression of CTLA-4 and the efficacy of immunotherapies like intravenous immunoglobulins and CTLA-4 blockade.

Main Results:

• Naturally occurring IgM antibodies bind tumor antigens, induce apoptosis in malignant cells, and detect precursor stages.
• Elevated levels of autoantibodies like anti-dsDNA and anti-Fas correlate with improved survival in carcinoma patients.
• Targeting CTLA-4 expression and employing immunotherapies show potential in improving cancer patient survival and preventing metastasis.

Conclusions:

• Naturally occurring autoantibodies play a crucial role in early cancer detection and possess anti-tumor activity.
• The interplay between autoimmunity and malignancy suggests shared mechanisms that can be therapeutically targeted.
• Immunotherapies targeting immune responses, such as CTLA-4 blockade, offer promising strategies for cancer treatment and metastasis prevention.